Atb Cap Markets Estimates Cresco Labs Q2 Earnings

Cresco Labs Inc. (OTCMKTS:CRLBF) – Equities researchers at Atb Cap Markets issued their Q2 2025 earnings per share estimates for Cresco Labs in a report released on Wednesday, March 12th. Atb Cap Markets analyst F. Gomes forecasts that the company will post earnings of ($0.03) per share for the quarter. Atb Cap Markets currently has a “Hold” rating on the stock. The consensus estimate for Cresco Labs’ current full-year earnings is ($0.20) per share. Atb Cap Markets also issued estimates for Cresco Labs’ Q3 2025 earnings at ($0.03) EPS and Q4 2025 earnings at ($0.03) EPS.

Cresco Labs Stock Up 6.6 %

Shares of Cresco Labs stock opened at $0.75 on Friday. The company has a debt-to-equity ratio of 1.80, a current ratio of 1.97 and a quick ratio of 1.39. Cresco Labs has a 1-year low of $0.70 and a 1-year high of $2.60. The business’s fifty day moving average price is $0.89 and its two-hundred day moving average price is $1.20. The company has a market capitalization of $364.25 million, a P/E ratio of -3.73 and a beta of 1.79.

About Cresco Labs

Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand.